Is Prelude Therapeutics, Inc. overvalued or undervalued?
As of November 6, 2024, Prelude Therapeutics, Inc. is considered a risky investment due to its negative financial metrics, including a Price to Book Value of 0.56, an EV to EBITDA ratio of 0.28, and a troubling Return on Equity of -123.89%, alongside a significant 78.01% decline in stock price over the past year.
As of 6 November 2024, the valuation grade for Prelude Therapeutics, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 0.56 and an EV to EBITDA ratio of 0.28. Additionally, the Return on Equity (ROE) stands at a concerning -123.89%, indicating significant losses relative to shareholder equity.In comparison to its peers, Prelude's valuation metrics are unfavorable. For instance, Trevi Therapeutics, Inc. has a P/E ratio of -15.40 and an EV to EBITDA of -12.29, while TriSalus Life Sciences, Inc. shows an EV to EBITDA of -7.00. Prelude's current price of $0.84 reflects a substantial drop of 78.01% over the past year, contrasting sharply with the S&P 500's 10.26% return in the same period, reinforcing the notion that the stock is overvalued in its current state.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
